The development of Jack Jumper ant venom immunotherapy: our 25 years' experience.
Jack Jumper ant
Myrmecia pilosula
insect sting allergy
venom immunotherapy
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
21
05
2023
accepted:
29
07
2023
medline:
26
9
2023
pubmed:
25
9
2023
entrez:
24
9
2023
Statut:
ppublish
Résumé
Jack Jumper ant venom allergy is a uniquely Australian medical issue. The stinging ant is a leading cause of insect venom allergy in south-eastern Australia. An effective venom immunotherapy-based treatment was successfully developed by the Tasmanian Jack Jumper Allergy Research group. This paper provides a synopsis of our 25 years' research journey in developing this evidence-based treatment modality.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1716-1721Informations de copyright
© 2023 Royal Australasian College of Physicians.
Références
Wanandy T, Mulcahy E, Lau WY, Brown SG, Wiese MD. Global view on ant venom allergy: from allergenic components to clinical management. Clin Rev Allergy Immunol 2022; 62: 123-144.
Wanandy T, Gueven N, Davies NW, Brown SG, Wiese MD. Pilosulins: a review of the structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula. Toxicon 2015; 98: 54-61.
Trinca J. Insect allergy in Australia: results of a five-year survey. Med J Aust 1964; 2: 659-663.
McGain F, Winkel KD. Ant sting mortality in Australia. Toxicon 2002; 40: 1095-1100.
Sutherland SK. Australian Animal Toxins: The Creatures, Their Toxins and Care of the Poisoned Patient. Melbourne: Oxford University Press; 1983.
Sutherland SK. Venom and antivenom research. Med J Aust 1980; 2: 246-250.
Lichtenstein LM, Valentine MD, Sobotka AK. A case for venom treatment in anaphylactic sensitivity to Hymenoptera sting. N Engl J Med 1974; 290: 1223-1227.
Sutherland SK. A Venomous Life. South Melbourne: Hyland House Publishing; 1998.
Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299: 157-161.
Clarke PS. The natural history of sensitivity to jack jumper ants (Hymenoptera formicidae Myrmecia pilosula) in Tasmania. Med J Aust 1986; 145: 564-566.
Sutherland S, Tibballs J. Australian Animal Toxins: The Creatures, Their Toxins and Care of the Poisoned Patient. Melbourne: Oxford University Press; 2001.
Weiner J, Baldo B, Donovan G, Sutherland S. Allergy to jumper ant (Myrmecia pilosula) stings in South-Eastern Australia. Ann Allergy Asthma Immunol 1995; 74: 60.
Warrell DA. Taking the sting out of ant stings: venom immunotherapy to prevent anaphylaxis. Lancet 2003; 361: 979-980.
Tibballs J. Struan Sutherland-doyen of envenomation in Australia. Toxicon 2006; 48: 860-871.
Matuszek MA, Hodgson WC, Sutherland SK, King RG. Pharmacological studies of jumper ant (Myrmecia pilosula) venom: evidence for the presence of histamine, and haemolytic and eicosaniod-releasing factors. Toxicon 1992; 30: 1081-1091.
Matuszek MA, Hodgson WC, King RG, Sutherland SK. Some enzymatic activities of two Australian ant venoms: a jumper ant Myrmecia pilosula and a bulldog ant Myrmecia pyriformis. Toxicon 1994; 32: 1543-1549.
Sutherland S. Allergy to the venom of jumper and bull ants. Med J Aust 1989; 150: 606.
Ford SA, Baldo BA, Weiner J, Sutherland SK. Identification of jack-jumper ant (Myrmecia pilosula) venom allergens. Clin Exp Allergy 1991; 21: 167-171.
Donovan GR, Baldo BA, Sutherland S. Molecular cloning and characterization of a major allergen (Myr p I) from the venom of the Australian jumper ant, Myrmecia pilosula. Biochim Biophys Acta Gene Struct Expression 1993; 1171: 272-280.
Donovan GR, Street MD, Baldo BA, Alewood D, Alewood P, Sutherland S. Identification of an IgE-binding determinant of the major allergen Myr p I from the venom of the Australian jumper ant Myrmecia pilosula. Biochim Biophys Acta 1994; 1204: 48-52.
Street MD, Donovan GR, Baldo BA. Molecular cloning and characterization of the major allergen Myr p II from the venom of the jumper ant Myrmecia pilosula: Myr p I and Myr p II share a common protein leader sequence. Biochim Biophys Acta Gene Struct Expression 1996; 1305: 87-97.
Donovan GR, Street MD, Tetaz T, Smith AI, Alewood D, Alewood P et al. Expression of jumper ant (Myrmecia pilosula) venom allergens: post-translational processing of allergen gene products. IUBMB Life 1996; 39: 877-885.
Donovan GR, Street MD, Baldo BA. Separation of jumper ant (Myrmecia pilosula) venom allergens: a novel group of highly basic proteins. Electrophoresis 1995; 16: 804-810.
Douglas RG, Weiner JM, Abramson MJ, O'Hehir RE. Prevalence of severe ant-venom allergy in southeastern Australia. J Allergy Clin Immunol 1998; 101: 129-131.
Brown SGA, Wu Q-X, Kelsall GRH, Heddle RJ, Baldo BA. Fatal anaphylaxis following jack jumper ant sting in southern Tasmania. Med J Aust 2001; 175: 644-647.
Brown SGA, Franks RW, Baldo BA, Heddle RJ. Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania. J Allergy Clin Immunol 2003; 111: 187-192.
Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114: 371-376.
Brown SGA. Preventing Anaphylaxis to Venom of the Jack Jumper Ant (Myrmecia pilosula). Adelaide: Flinders University; 2003.
Brown SG, Heddle RJ. Prevention of anaphylaxis with ant venom immunotherapy. Curr Opin Allergy Clin Immunol 2003; 3: 511-516.
Brown S, Blackman K, Stenlake V, Heddle R. Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg Med J 2004; 21: 149-154.
Brown SGA, Wiese MD, Blackman KE, Heddle RJ. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003; 361: 1001-1006.
Davies NW, Wiese MD, Brown SGA. Characterisation of major peptides in ‘jack jumper’ ant venom by mass spectrometry. Toxicon 2004; 43: 173-183.
Wiese MD. Characterisation of the Allergic Components and Pharmaceutical Development of Myrmecia pilosula (Jack Jumper) Ant Venom for Immunotherapy. Adelaide: University of South Australia; 2007.
Wiese MD, Chataway TK, Davies NW, Milne RW, Brown SGA, Gai W-P et al. Proteomic analysis of Myrmecia pilosula (jack jumper) ant venom. Toxicon 2006; 47: 208-217.
Inagaki H, Akagi M, Imai HT, Taylor RW, Wiese MD, Davies NW et al. Pilosulin 5, a novel histamine-releasing peptide of the Australian ant, Myrmecia pilosula (Jack Jumper Ant). Arch Biochem Biophys 2008; 477: 411-416.
Wiese M, Brown S, Chataway T, Davies N, Milne R, Aulfrey S et al. Myrmecia pilosula (Jack Jumper) ant venom: identification of allergens and revised nomenclature. Allergy 2007; 62: 437-443.
Wanandy T, Wilson R, Gell D, Rose HE, Gueven N, Davies NW et al. Towards complete identification of allergens in Jack Jumper (Myrmecia pilosula) ant venom and their clinical relevance: an immunoproteomic approach. Clin Exp Allergy 2018; 48: 1222-1234.
Wiese MD, Milne RW, Davies NW, Chataway TK, Brown SGA, Heddle RJ. Myrmecia pilosula (Jack Jumper) ant venom: validation of a procedure to standardise an allergy vaccine. J Pharm Biomed Anal 2008; 46: 58-65.
Mullins R, Brown SG. Ant venom immunotherapy in Australia: the unmet need. Med J Aust 2014; 201: 33-34.
Wanandy T, Dwyer H, McLean L, Davies N, Nichols D, Gueven N et al. Factors influencing the quality of Myrmecia pilosula (Jack Jumper) ant venom for use in in vitro and in vivo diagnoses of allergen sensitization and in allergen immunotherapy. Clin Exp Allergy 2017; 47: 1478-1490.
Wiese MD, Davies NW, Chataway TK, Milne RW, Brown SGA, Heddle RJ. Stability of Myrmecia pilosula (Jack Jumper) ant venom for use in immunotherapy. J Pharm Biomed Anal 2011; 54: 303-310.
Brown SGA, van Eeden P, Wiese MD, Mullins RJ, Solley GO, Puy R et al. Causes of ant sting anaphylaxis in Australia: the Australian Ant Venom Allergy Study. Med J Aust 2011; 195: 69-73.
van Eeden PE, Wiese MD, Aulfrey S, Hales BJ, Stone SF, Brown SG. Using time-resolved fluorescence to measure serum venom-specific IgE and IgG. PLoS One 2011; 6: e16741.
Brown SG, Wiese MD, Van Eeden P, Stone SF, Chuter CL, Gunner J et al. Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial. J Allergy Clin Immunol 2012; 130: 162-168.
ASCIA Position Statement: Jack Jumper Ant Venom Immunotherapy; 2015.
Wanandy T, Honda-Okubo Y, Davies NW, Rose HE, Heddle RJ, Brown SG et al. Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy. J Pharm Biomed Anal 2019; 172: 1-8.
Lau W, Mulcahy E, Wanandy T, Tran V. Severe systemic allergic reactions to Jack Jumper Ant Venom Immunotherapy: basophil response during treatment with Omalizumab. Intern Med J 2018; 48: 13.
Le T, Vareeckal-Joseph S, Wiese M, Petrovsky N, Woodman R, Wanandy T et al. Basophil activation testing as a biomarker for diagnostic and prognostic evaluation of ant (Myrmecia pilosula) venom anaphylaxis before and after immunotherapy. Allergy 2019; 74: 239.